Global lipidomics identified plasma lipids as novel biomarkers for early detection of lung cancer
Metrics: PDF 1009 views | HTML 2659 views | ?
Zongtao Yu1,2,*, Hankui Chen2,*, Junmei Ai2,*, Yong Zhu3,*, Yan Li2, Jeffrey A. Borgia4, Jin-Song Yang5, Jicai Zhang1, Bin Jiang3, Wei Gu6 and Youping Deng3,1,7
1Department of Laboratory Medicine, Shiyan Taihe Hospital, College of Biomedical Engineering, Hubei University of Medicine, Shiyan 442000, Hubei, China
2Department of Internal Medicine, Rush University Medical Center, Chicago, IL 60612, USA
3National Center of Colorectal Disease, Nanjing Municipal Hospital of Chinese Medicine, The Third Affiliated Hospital, Nanjing University of Chinese Medicine, Guangdong, Nanjing 210001, China
4Department of Pathology, Rush University Medical Center, Chicago, IL 60612, USA
5Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China
6Department of Respiration, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu 210006, China
7Department of Complementary & Integrative Medicine, University of Hawaii John A. Burns School of Medicine, Honolulu, HI 96813, USA
*These authors have contributed equally to this work
Youping Deng, email: email@example.com
Wei Gu, email: firstname.lastname@example.org
Bin Jiang, email: email@example.com
Keywords: lipidomics; lung cancer; early biomarkers; ESI-MS
Received: April 04, 2017 Accepted: August 26, 2017 Published: November 11, 2017
Purpose: Lipids play roles in membrane structure, energy storage, and signal transduction as well as in human cancers. Here we adopt lipidomics to identify plasma lipid markers for early screening and detection of lung cancer.
Experimental Design: Using mass spectrometry, we profiled 390 individual lipids using training and validation strategy in a total of 346 plasma samples from 199 early NSCLC patients, including 113 adenocacinoma and 86 squamous cell cancers (SqCC), and from 147 healthy controls.
Results: In the training stage, we found distinct lipid groups that were significantly distributed between NSCLC cases and healthy controls. We further defined a panel of four lipid markers (LPE(18:1), ePE(40:4), C(18:2)CE and SM(22:0)) for prediction of early cancer with a accuracy of 82.3% AUC (Area under ROC curve), sensitivity of 81.9% and specificity of 70.7% at the training stage and yielded the predictive power with accuracy (AUC,80.8%), sensitivity 78.7%, specificity 69.4% and in the validation stage.
Conclusions: Using lipidomics we identified several lipid markers capable of discerning early stage lung carcinoma from healthy individuals, which might be further developed as a quick, safe blood test for early diagnosis of this disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.